| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8efb4af0f4e69e07dadbeb9f2740340d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aeedaf1de301ddc0b2ad5448bc22d027 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate |
2005-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f297e5f5d462aa36046016c5fe97edc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8cf928a01d6ffb267a3145ddd2422b8 |
| publicationDate |
2006-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006229276-A1 |
| titleOfInvention |
Use of glycosoaminoglycans for the prevention and treatment of sepsis |
| abstract |
The present invention discloses an unexpected use of glycosoaminoglycans such as low molecular weight heparin in the prevention and treatment of sepsis. Low molecular weight heparin is capable of preventing mortality and prolonging survival in a mouse model of S. aureus -induced septic death. Two other glycosaminoglycans, namely chondroitin sulfate A and dermatan sulfate were also shown to exhibit a therapeutic effect in septic mice. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112437667-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021194890-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019246264-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633424-B2 |
| priorityDate |
2004-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |